GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (LSE:RENE) » Definitions » Debt-to-EBITDA

ReNeuron Group (LSE:RENE) Debt-to-EBITDA : -0.06 (As of Sep. 2023)


View and export this data going back to 2005. Start your Free Trial

What is ReNeuron Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

ReNeuron Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was £0.16 Mil. ReNeuron Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was £0.19 Mil. ReNeuron Group's annualized EBITDA for the quarter that ended in Sep. 2023 was £-6.18 Mil. ReNeuron Group's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.06.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for ReNeuron Group's Debt-to-EBITDA or its related term are showing as below:

LSE:RENE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.07   Med: -0.06   Max: -0.05
Current: -0.06

During the past 13 years, the highest Debt-to-EBITDA Ratio of ReNeuron Group was -0.05. The lowest was -0.07. And the median was -0.06.

LSE:RENE's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.375 vs LSE:RENE: -0.06

ReNeuron Group Debt-to-EBITDA Historical Data

The historical data trend for ReNeuron Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Debt-to-EBITDA Chart

ReNeuron Group Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 -0.07 -0.06 -0.05 -0.07

ReNeuron Group Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.06 -0.07 -0.08 -0.06

Competitive Comparison of ReNeuron Group's Debt-to-EBITDA

For the Biotechnology subindustry, ReNeuron Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ReNeuron Group's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ReNeuron Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ReNeuron Group's Debt-to-EBITDA falls into.



ReNeuron Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

ReNeuron Group's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.153 + 0.268) / -6.37
=-0.07

ReNeuron Group's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.156 + 0.189) / -6.182
=-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Sep. 2023) EBITDA data.


ReNeuron Group  (LSE:RENE) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


ReNeuron Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


ReNeuron Group (LSE:RENE) Business Description

Traded in Other Exchanges
Address
Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.